Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/122851Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Mezquita-Raya, Pedro | - |
| dc.contributor.author | Darbà, Josep | - |
| dc.contributor.author | Ascanio, Meritxell | - |
| dc.contributor.author | Ramírez de Arellano, Antonio | - |
| dc.date.accessioned | 2018-06-08T07:50:15Z | - |
| dc.date.available | 2018-11-30T06:10:18Z | - |
| dc.date.issued | 2017-11 | - |
| dc.identifier.issn | 1473-7167 | - |
| dc.identifier.uri | https://hdl.handle.net/2445/122851 | - |
| dc.description.abstract | The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. Methods: A short-term cost utility model was developed to estimate effectiveness results in terms of the total number of hypoglycaemic events and their disutility impact throughout the year on the initial level of quality of life for patients in each treatment . | - |
| dc.format.extent | 9 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | Informa Healthcare | - |
| dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1080/14737167.2017.1345628 | - |
| dc.relation.ispartof | Expert Review of Pharmacoeconomics & Outcomes Research, 2017, vol. 17, num. 6, p. 587-595 | - |
| dc.relation.uri | https://doi.org/10.1080/14737167.2017.1345628 | - |
| dc.rights | (c) Informa Healthcare, 2017 | - |
| dc.source | Articles publicats en revistes (Economia) | - |
| dc.subject.classification | Anàlisi cost-benefici | - |
| dc.subject.classification | Salut pública | - |
| dc.subject.classification | Diabetis | - |
| dc.subject.classification | Insulina | - |
| dc.subject.other | Cost effectiveness | - |
| dc.subject.other | Public health | - |
| dc.subject.other | Diabetes | - |
| dc.subject.other | Insulin | - |
| dc.title | Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/acceptedVersion | - |
| dc.identifier.idgrec | 676690 | - |
| dc.date.updated | 2018-06-08T07:50:15Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| dc.identifier.pmid | 28649881 | - |
| Appears in Collections: | Articles publicats en revistes (Economia) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 676690.pdf | 856.35 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.